NCT01609452View on ClinicalTrials.gov

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2015

Primary Completion Date

June 30, 2016

Conditions
Immune Thrombocytopenic PurpuraIdiopathic Thrombocytopenic Purpura
Interventions
BIOLOGICAL

Blisibimod

OTHER

Placebo

Sponsors
All Listed Sponsors
lead

Anthera Pharmaceuticals

INDUSTRY

NCT01609452 - MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP | Biotech Hunter | Biotech Hunter